IL308257A - Antigen binding proteins specifically binding prame - Google Patents

Antigen binding proteins specifically binding prame

Info

Publication number
IL308257A
IL308257A IL308257A IL30825723A IL308257A IL 308257 A IL308257 A IL 308257A IL 308257 A IL308257 A IL 308257A IL 30825723 A IL30825723 A IL 30825723A IL 308257 A IL308257 A IL 308257A
Authority
IL
Israel
Prior art keywords
seq
amino acid
antigen binding
acid sequence
binding protein
Prior art date
Application number
IL308257A
Other languages
English (en)
Hebrew (he)
Inventor
Gabriele Pszolla
Martin Hofmann
Meike Hutt
Sebastian Bunk
Felix Unverdorben
Frank SCHW?BEL
Dominik Maurer
Maike Jaworski
Claudia Wagner
Florian SCHW?RER
Heiko Schuster
Original Assignee
Immatics Biotechnologies Gmbh
Gabriele Pszolla
Martin Hofmann
Meike Hutt
Sebastian Bunk
Felix Unverdorben
Frank SCHW?BEL
Dominik Maurer
Maike Jaworski
Claudia Wagner
Florian SCHW?RER
Heiko Schuster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh, Gabriele Pszolla, Martin Hofmann, Meike Hutt, Sebastian Bunk, Felix Unverdorben, Frank SCHW?BEL, Dominik Maurer, Maike Jaworski, Claudia Wagner, Florian SCHW?RER, Heiko Schuster filed Critical Immatics Biotechnologies Gmbh
Publication of IL308257A publication Critical patent/IL308257A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL308257A 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame IL308257A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184689P 2021-05-05 2021-05-05
EP21172351 2021-05-05
PCT/EP2022/062017 WO2022233956A1 (en) 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame

Publications (1)

Publication Number Publication Date
IL308257A true IL308257A (en) 2024-01-01

Family

ID=81579586

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308257A IL308257A (en) 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame

Country Status (14)

Country Link
US (4) US12570760B2 (enExample)
EP (1) EP4334361A1 (enExample)
JP (1) JP2024518378A (enExample)
KR (1) KR20240004935A (enExample)
AU (1) AU2022270361A1 (enExample)
BR (1) BR112023022765A2 (enExample)
CA (1) CA3217738A1 (enExample)
CL (1) CL2023003232A1 (enExample)
CO (1) CO2023014722A2 (enExample)
IL (1) IL308257A (enExample)
MX (1) MX2023012902A (enExample)
PE (1) PE20242343A1 (enExample)
TW (1) TW202309071A (enExample)
WO (1) WO2022233956A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554328B (zh) * 2023-05-11 2023-09-29 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向trbv12的单链抗体、car、car-nk细胞及应用
CN118221811B (zh) * 2023-08-25 2025-05-30 立凌生物制药(苏州)有限公司 靶向prame多肽的单域抗体及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
WO2026104504A1 (en) 2024-11-15 2026-05-21 Immatics Biotechnologies Gmbh Dosing of prame-specific tcer
WO2026150149A1 (en) * 2025-01-13 2026-07-16 Immatics Biotechnologies Gmbh Bispecific tcer against a magea4- and a prame-derived peptide in combination with an immune checkpoint inhibitor for use in treating cancer
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244A (en) 1837-06-30 Edward flint
US5204A (en) 1847-07-24 james cantelo
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DK1247095T3 (da) 1999-12-06 2008-12-08 Univ Illinois TCR-proteiner med höj affinitet samt fremgangsmåder
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
WO2006014579A2 (en) 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
NZ587601A (en) 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
US20110245153A1 (en) 2006-03-15 2011-10-06 National Institutes of Health (NIH), U. S. Dept. of Health and Human Resources (DHHS) U. S. Govt. Neutralizing Agents for Bacterial Toxins
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20080187535A1 (en) 2007-01-15 2008-08-07 Normand Blais Vaccine
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2152751A1 (en) 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
CA2700278A1 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
EP2235181A1 (en) 2008-01-11 2010-10-06 MorphoSys AG Display vectors and methods and uses thereof
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
EA201401134A1 (ru) 2011-02-11 2015-05-29 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
NZ741124A (en) 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105339498A (zh) 2013-03-07 2016-02-17 贝勒医学院 癌症中靶向cd138
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
ES2927971T3 (es) 2014-03-25 2022-11-14 Boehringer Ingelheim Animal Health Usa Inc Composiciones inmunológicas que contienen Histophilus Somni atenuado
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AU2016230828B2 (en) 2015-03-10 2020-10-22 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
CN114634569B (zh) 2016-04-15 2024-08-20 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
JP6989138B2 (ja) 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体及びその使用
EP3475938B1 (en) 2016-06-27 2020-12-23 The Procter and Gamble Company Apparatus and method for assessing tooth-sensitivity treatment by oral-care product
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
JP7012364B2 (ja) 2016-08-05 2022-02-14 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
CN118546961A (zh) 2016-08-26 2024-08-27 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CN111094333A (zh) 2017-06-01 2020-05-01 斯图加特大学 异源二聚化的Ig结构域
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2019047932A1 (zh) 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
BR112020005552A2 (pt) 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
KR102742741B1 (ko) 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
IL326873A (en) 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
SG11202007622SA (en) 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
CN110156889B (zh) 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 高亲和力HBs T细胞受体
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
AU2019256536C1 (en) 2018-04-19 2026-01-15 Baylor College Of Medicine Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
CA3100253A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020021045A2 (en) 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesù (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
WO2020081537A1 (en) 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
JP7863702B2 (ja) 2018-11-08 2026-05-22 セルキュア インコーポレイテッド 表現型特性が向上したｔ細胞組成物
SG11202105975SA (en) 2018-12-06 2021-07-29 Guangdong Tcrcure Biopharma Technology Co Ltd Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
US12590292B2 (en) 2019-01-07 2026-03-31 Children's National Medical Center Targeted T-cell therapy for treatment of multiple myeloma
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12018061B2 (en) 2019-03-08 2024-06-25 St Phi Therapeutics Co., Ltd. Chimeric endocytic receptors and method of use thereof
WO2020186158A2 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
WO2020186204A1 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3941490A4 (en) 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELLULAR THERAPY
EP3959307A4 (en) 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
US20210040558A1 (en) 2019-07-15 2021-02-11 Neogene Therapeutics B.V. Method to isolate tcr genes
EP3999079A4 (en) 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
JP2022542867A (ja) 2019-07-23 2022-10-07 ドイチェス クレブスフォルシュンクスツェントルム Ａｍｌの処置のためのポリペプチド
MX2022000852A (es) 2019-07-24 2022-02-10 Eureka Therapeutics Inc Celulas que expresan receptores de antigenos quimericos y receptores estimulantes quimericos y usos de los mismos.
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
CA3149939A1 (en) 2019-09-06 2021-03-11 Stephen J. Demarest Proteins comprising t-cell receptor constant domains
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
MX2022003149A (es) 2019-09-27 2022-04-06 Agenus Inc Proteinas heterodimericas.
US20210147929A1 (en) 2019-10-11 2021-05-20 Saint Louis University Immune receptor analysis as diagnostic assay
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
CA3157411A1 (en) 2019-11-15 2021-05-20 Karin Jooss Antigen-binding proteins targeting shared neoantigens
CU20220029A7 (es) 2019-11-18 2023-01-16 BioNTech SE Receptores de tcr de prame
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
MX2022009825A (es) 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
WO2021163456A1 (en) 2020-02-14 2021-08-19 Epivax, Inc. T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
US20230159614A1 (en) 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021188601A1 (en) 2020-03-16 2021-09-23 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021188599A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
WO2021211455A1 (en) 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
CN116171165A (zh) 2020-06-10 2023-05-26 墨尔本大学 Hiv-1抗体
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
EP4185614A4 (en) 2020-07-24 2024-12-18 Tscan Therapeutics, Inc. BINDING PROTEINS RECOGNIZING SARS-COV-2 ANTIGENS AND THEIR USES
JP2023536100A (ja) 2020-07-27 2023-08-23 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
US20230374140A1 (en) 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
JP2023550515A (ja) 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
WO2022133592A1 (en) 2020-12-21 2022-06-30 Zymeworks Inc. Stabilized tcr constructs and methods of use
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
US20240327490A1 (en) 2021-01-08 2024-10-03 The Johns Hopkins University Sars-cov-2-specific t cell receptors and related materials and methods of use
IL305175A (en) 2021-02-19 2023-10-01 Angeles Therapeutics Inc Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
WO2023076875A1 (en) 2021-10-25 2023-05-04 The Regents Of The University Of California Methods and compositions for treating glioblastoma
WO2023139289A1 (en) 2022-01-24 2023-07-27 Eth Zurich Universal tcr variants for allogeneic immunotherapy
WO2023173024A2 (en) 2022-03-10 2023-09-14 The Board Of Trustees Of The Leland Stanford Junior University Treatment of coronary artery disease by reducing activity of cross-reactive t cells

Also Published As

Publication number Publication date
CO2023014722A2 (es) 2024-02-05
BR112023022765A2 (pt) 2024-01-02
US20230357428A1 (en) 2023-11-09
CL2023003232A1 (es) 2024-04-19
KR20240004935A (ko) 2024-01-11
JP2024518378A (ja) 2024-05-01
US20220372165A1 (en) 2022-11-24
WO2022233956A1 (en) 2022-11-10
EP4334361A1 (en) 2024-03-13
US11859009B2 (en) 2024-01-02
MX2023012902A (es) 2023-11-08
US20230091330A1 (en) 2023-03-23
US12570760B2 (en) 2026-03-10
AU2022270361A1 (en) 2023-11-16
US20240092933A1 (en) 2024-03-21
CA3217738A1 (en) 2022-05-04
PE20242343A1 (es) 2024-12-16
TW202309071A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
US12269881B2 (en) Antigen binding proteins specifically binding MAGE-A
US11859009B2 (en) Antigen binding proteins specifically binding PRAME
US20230203200A1 (en) Recruiting agent further binding an mhc molecule
WO2021226193A1 (en) Proteins binding nkg2d, cd16 and clec12a
WO2025021968A1 (en) Antigen binding proteins against mageb2
CN117651718A (zh) 特异性结合prame的抗原结合蛋白
US20250034227A1 (en) Antigen binding proteins against mageb2
HK40091509A (en) Antigen binding proteins that specifically bind to mage-a
EA049528B1 (ru) Антигенсвязывающие белки, специфически связывающие mage-a